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Cervical screening aims to identify women with high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia
2-3 (HSIL/CIN2-3) or invasive cervical cancer (ICC). Identiﬁcation of women with severe premalignant lesions or ICC (CIN3+)
could ensure their rapid treatment and prevent overtreatment. We investigated high-risk human papillomavirus (hrHPV)
detection with genotyping and methylation of FAM19A4/miR124-2 for detection of CIN3+ in 538 women attending colposcopy
for abnormal cytology. All women had an additional cytology with hrHPV testing (GP5+/6+-PCR-EIA+), genotyping (HPV16/18,
HPV16/18/31/45), and methylation analysis (FAM19A4/miR124-2) and at least one biopsy. CIN3+ detection was studied
overall and in women <30 (n = 171) and ≥30 years (n = 367). Positivity for both rather than just one methylation markers
increased in CIN3, and all ICC was positive for both. Overall sensitivity and speciﬁcity for CIN3+ were, respectively, 90.3%
(95%CI 81.3–95.2) and 31.8% (95%CI 27.7–36.1) for hrHPV, 77.8% (95%CI 66.9–85.8) and 69.3% (95%CI 65.0–73.3) for
methylation biomarkers and 93.1% (95%CI 84.8–97.0) and 49.4% (95%CI 44.8–53.9) for combined HPV16/18 and/or methylation
positivity. For CIN3, hrHPV was found in 90.9% (95%CI 81.6–95.8), methylation positivity in 75.8% (95%CI 64.2–84.5) and
HPV16/18 and/or methylation positivity in 92.4% (95%CI 83.5–96.7). In women aged ≥30, the sensitivity of combined HPV16/18
and methylation was increased (98.2%, 95%CI 90.6–99.7) with a speciﬁcity of 46.3% (95%CI 40.8–51.9). Combination of
HPV16/18 and methylation analysis was very sensitive and offered improved speciﬁcity for CIN3+, opening the possibility of rapid
treatment for these women and follow-up for women with potentially regressive, less advanced, HSIL/CIN2 lesions.
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FAM19A4: family with sequence similarity 19 (chemokine (C–C)-motif )-like), member A4; hrHPV: high-risk human papillomavirus; HSIL:
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methylation-speciﬁc PCR
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Background
The mortality rate from invasive cervical cancer (ICC) has
decreased signiﬁcantly in developed countries through the
introduction of organized cervical screening programs, mostly
based on conventional cytology.1,2 Women with abnormal
cytology or with a positive result in the testing for high-risk
human papillomavirus (hrHPV) are either referred directly, or
after triage, for colposcopy and biopsy to identify high-grade
squamous intraepithelial lesion/cervical intraepithelial neopla-
sia grade 2 or 3 (HSIL/CIN2-3) or ICC.3 A biopsy diagnosis
of HSIL/CIN2-3 is the current threshold for excision of a pre-
cancerous lesion.4
However, most HSIL/CIN2-3 will not progress to ICC if
not treated.5,6 HSIL/CIN2-3 lesions are heterogeneous, espe-
cially those graded as CIN2, and include both productive
hrHPV infections as well as early and advanced transforming
hrHPV lesions. Productive infections and early transforming
infections may regress spontaneously and immediate surgical
removal may incur harm and increase the risk of adverse out-
come for any future pregnancy.7 Preventing such unwanted
outcomes would be valuable. In contrast, advanced transform-
ing lesions with a high short-term risk of progression should
be treated without delay. A triage strategy able to provide
accurate risk stratiﬁcation, identifying the different subgroups
of women with HSIL/CIN2-3, could reduce harm, especially
in young women of reproductive age.
A number of different molecular markers are currently
being investigated to optimize risk stratiﬁcation for patients
with hrHPV infection and cervical lesions. These include
hrHPV genotyping, expression of viral genes and methylation
of viral genes or human tumor suppressor genes.8 A high pro-
portion of ICC and a large number of HSIL are associated
with HPV16/18, even in the presence of multiple HPV infec-
tions, and HPV16 is also associated with larger HSIL/CIN3
lesions in younger women.9–11 Several human tumor suppres-
sor genes have shown hypermethylation of the CpG islands in
the promotor regions, which are of value in identifying
women with ICC and advanced HSIL/CIN3 deﬁned as long
duration of preceding hrHPV infection.12 Hypermethylation
of the genes FAM19A4 and miR124-2 have shown promising
results as single triage markers or in combination with other
tumor suppressor genes in physician-taken samples in detect-
ing HSIL/CIN3, particularly in women with HPV infections
of long duration.13–15
The EVAH study (Evaluating the Visual Appearance of
Cervical Lesions in Relation its Histological Diagnosis, Human
Papillomavirus Genotype and Other Viral Parameters)16 pro-
vides a basis for the evaluation of various tests that could be
used for risk stratiﬁcation. It allows comparison of standard
clinical and pathological information with new molecular tests
and colposcopy follow-up for up to 2 years and provides a
framework for the long-term outcome of different triage tests.
This study aimed to detect women with HSIL/CIN3 or
ICC (CIN3+) in a cytology-screened (atypical squamous cells
of unknown signiﬁcance or more severe lesions [≥ASC-US])
referral population by using referral cytological grade,
hrHPV testing and genotyping and methylation testing of
human tumor suppressor genes FAM19A4 and miR124-2 per-
formed on physician-taken smears obtained at colposcopy.
Sensitivities, speciﬁcities, positive and negative predictive
values (PPV and NPV) of the different triage tests for CIN3+
detection were calculated for women <30 and ≥30 years
of age.
Methods
The EVAH study is a prospective multicenter observational
cohort study16 conducted in Voorburg, The Netherlands, and
Barcelona, Spain. Inclusion criteria were (i) an abnormal cyto-
logical test result (≥ASC-US) and (ii) 18 years of age or older.
The criteria of exclusion were (i) previous diagnosis of ICC,
(ii) history of surgery to the cervix or previous pelvic radio-
therapy, (iii) current pregnancy or pregnancy in the previous
3 months, (iv) current breastfeeding or breastfeeding in the
previous 3 months and (v) insufﬁcient material for hrHPV
testing and methylation analysis.
From each subject, data were collected on ethnicity, rele-
vant medical history, number of sexual partners and contra-
ception, using a standardized questionnaire. Results from the
ﬁrst 601 inclusions from Barcelona were analyzed in this
study.
Colposcopy
Women included in the study were seen in the colposcopy
clinic, where a physician-taken smear was collected and digital
colposcopy was performed. During colposcopy, at least one
cervical biopsy was taken from each patient. Up to four
directed biopsies were taken from suspected lesions. If less
than four directed biopsies were taken, a random biopsy was
also taken from normal appearing tissue. Colposcopy ﬁndings
were described using the criteria of the International Federa-
tion for Cervical Pathology and Colposcopy (IFCPC).17
What’s new?
Reliable triage of women with cervical intraepithelial neoplasia (CIN) is of high priority as not all lesions progress to invasive
carcinoma. Here the authors show that combining the methylation status of tumor suppressor genes FAM19A4 and miR124-2
with genotyping for high-risk human papillomavirus results in a highly sensitive and moderately speciﬁc triage strategy that
identiﬁes women with CIN lesions likely to need rapid treatment. The authors recommend clinical evaluation of the strategy in
prospective studies.
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Physician-taken smear
A trained physician collected a cervical smear using a Cervex-
Brush (Rovers Medical Devices B.V., Oss, The Netherlands).
The Cervex-Brush was rinsed in 20 mL of ThinPrep medium
(Hologic, Marlborough, MA). Samples were stored at room
temperature for up to 6 months. An aliquot of 2 mL was sent
to DDL Diagnostic Laboratory, Rijswijk, The Netherlands for
molecular testing. At arrival at DDL, the samples were stored
at 4C.
Biopsy
Biopsies were ﬁxed in 10% formalin, embedded in parafﬁn
and sectioned for hematoxylin and eosin (H&E) and addi-
tional immunohistochemical staining at the local laboratory.
p16 immunohistochemical staining was performed and slides
were scored as negative, patchy staining, block staining
restricted to lower 1/3 the lower 2/3, or extending above the
lower 2/3 of the epithelium up to full thickness staining. Sec-
tions were reviewed independently by two expert gynecologi-
cal pathologists and classiﬁed as either normal, CIN 1, CIN
2, CIN 3, adenocarcinoma in situ (AIS) or ICC. In case of dis-
crepancies between the two pathologists, a third gynecological
expert pathologist was consulted, resulting in a majority con-
sensus diagnosis.
Sample preparation and hrHPV detection
From the physician-taken smears, DNA was isolated for
hrHPV testing. An input volume of 250 μL was used to obtain
100 μL of eluate with the QIAamp MinElute Virus Spin kit
(QIAgen Inc., Valencia, CA). hrHPV detection was performed
using the GP5+/6+-PCR-EIA (Labo Bio-medical Products,
Rijswijk, The Netherlands). The EIA-positive GP5+/6+ ampli-
mers were genotyped using a strip-based test by the Genotyp-
ing kit HPV GP (Labo Bio-medical Products, Rijswijk, The
Netherlands) genotyping hrHPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66 and 68.
Methylation
The residual cervical sample was concentrated at Hospital
Clínic and sent to DDL Diagnostic Laboratory for methylation
testing.
DNA was isolated using the MagNA Pure 96 (500 μL
input, 50 μL eluate) for methylation testing. The level of
ampliﬁable human DNA was assessed using a qPCR of the in-
house reference gene RNaseP with the Phocine herpes virus as
an internal control for the absence of PCR-inhibition.18
All samples with a DNA concentration of 5.5 ng/μL or
higher were subjected to bisulﬁte conversion using the EZ
DNA Methylation kit (Zymo Research, Orange, CA). Up to
250 ng/45 μL of DNA was used. A standardized multiplex
qMSP (QIAsure), targeting for the promotor regions of
FAM19A4 and miR124-2 (QIAgen Inc., Valencia, CA), was
performed on the bisulﬁte-converted DNA according to the
manufacturer’s protocol. The bisulﬁte-converted human
reference gene beta-actin (ACTB) was included in the multi-
plex to determine the total amount of converted human DNA.
The samples were scored hypermethylation positive when CT
value of the housekeeping gene β-actin was ≤26.4 and at least
one of the marker genes (i.e., FAM19A4 and hsa-mir124-2)
had a ΔΔCT below the cutoff according to the kit insert.
Methylation positivity was then correlated to the histological
diagnosis outcome.
Statistical analysis
Results of cytology, hrHPV testing and methylation testing
were studied for their performance in the detection of CIN3+
lesions. For analysis cytological outcome was classiﬁed as
ASC-US/LSIL (ASC-US and LSIL) or ASC-H/HSIL (HSIL,
ASC-H and AGC). Interpretation of the hrHPV testing
resulted in hrHPV positive or negative and interpretation of
the genotyping resulted in HPV16/18/31/45 or no-
HPV16/18/31/45 and HPV16/18 or no-HPV16/18. Smears
that tested positive for FAM19A and/or miR124-2 according
to the standardized criteria were considered as methylation
positive, whereas methylation negative smears were deﬁned as
samples negative for both markers. After categorizing women
using these test results, different combinations were made to
compute sensitivity, speciﬁcity, PPV and NPV with corre-
sponding 95% conﬁdence intervals. Diagnostic performance
was calculated for the entire cohort and for women aged <30
or ≥30 years. In addition, results are shown for all women
with ASC-US/LSIL referral cytology and women with ASC-H/
HSIL referral cytology.
Statistical analysis was performed using the SPSS software
(Version 22.0, SPSS, Inc, Chicago, IL). The results are pre-
sented as absolute numbers and percentages or mean and
standard deviation. χ2 tests, independent sample t-tests and
McNemar’s tests were used, as appropriate, for comparisons
between categorical, between scale variables and for compari-
son of the performance of diagnostic tests. A p value <0.05
was considered statistically signiﬁcant.
Results
Characteristics of the EVAH study participants
Of the 601 selected women, 540 (89.8%) had a physician-
taken smear with a DNA concentration ≥5.5 ng/μL and were
suitable for methylation testing. Methylation testing resulted
in 538 valid results (340, 63.2% negative; 198, 36.8% positive)
that were used for further analysis. Two invalid results based
on a negative result of the reference gene ACTB were
excluded. The ﬂowchart of the women included in the study
with the cross-sectional results of the referral smear, hrHPV
testing and genotyping and methylation testing are shown in
Figure 1.
Mean age of women at the time of the ﬁrst visit to the col-
poscopy clinic was 36.2 years (95% CI 35.3–37.2; range
18–75). Histological diagnoses of the cervical biopsies were
normal squamous epithelium in 234 women (43.5%), CIN1 in
162 hrHPV genotyping and methylation in detecting CIN3+
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101 (18.8%), CIN2 in 131 (24.3%), CIN3 in 66 (12.3%) and
ICC (invasive cervical carcinoma) in 6 (1.1%).
hrHPV testing using the clinical test GP5+/6+-PCR-EIA,
was positive in 383 women (71.2%), and the remaining
155 women (28.8%) were hrHPV negative. Of the hrHPV-
positive samples, 188 (49.1%) tested positive for HPV16/18
and 195 (50.9%) tested positive for non-HPV16/18 hrHPV
genotypes.
Sensitivity and speciﬁcity of hrHPV testing and methyla-
tion for the detection of CIN3+ in women with abnormal
cytology.
Single triage markers
The performance of hrHPV detection, genotyping for
HPV16/18 and HPV16/18/31/45 and methylation testing as
single triage tests were explored for this population for the
outcome of CIN3+ including CIN3 lesions and carcinomas
(Table 1) and for CIN3 only (Table 2). hrHPV positivity with
GP5+/6+-PCR-EIA was found in 65/72 women with CIN3+
and in 148/466 of the women with a ≤CIN2 lesion no hrHPV
was found (sensitivity 90.3%, speciﬁcity 31.8%).
HPV16/18/31/45 was detected in the physician-taken smear in
54/72 women with CIN3+ lesions and in 259/466 with ≤CIN2
lesions these types were not detected (sensitivity 75.0%, speci-
ﬁcity 55.6%). HPV16/18 was present in 45/72 of women with
CIN3+ lesions and 323/466 women with ≤CIN2 lesions were
HPV16/18 negative (sensitivity 62.5%, speciﬁcity 69.3%).
Methylation testing was positive in 56/72 of women CIN3+
lesions and 323/466 of women with ≤CIN2 lesions were meth-
ylation negative overall (sensitivity 77.8%, speciﬁcity 69.3%).
Methylation detected all ICC and 75.8% (50/66) of CIN3.
There was a signiﬁcant difference in mean age between
women with a methylation positive CIN3+ lesion (41 years)
and women with methylation negative CIN3+ lesions
(30 years, p < 0.001). Among the women with ≤CIN2, methyl-
ation was positive in 24.4% of women with negative and CIN1
biopsies and in 44.3% of women with CIN2. Again, a signiﬁ-
cant difference in mean age between methylation positive
(41 years) and methylation negative women (34 years) was
found (p < 0.001).
FAM19A4 and miR124-2 positivity in different grades of
CIN were assessed separately in order to detect trends in posi-
tivity of the individual markers and the combination of the
two biomarkers (Fig. 2). FAM19A4 was the commonest indi-
vidual positive marker. 50/85 (58.8%) biopsies without dys-
plastic lesions and CIN1 lesions that were methylation
positive showed positivity for FAM19A4 only. Positivity for
both FAM19A4 and miR124-2 was seen in most CIN3 lesions
and all ICC. We found that 19.7% (13/66) of CIN3 lesions
were detected by FAM19A4 only, while miR124-2 only
showed positivity in ﬁve low-grade lesions and one CIN2
lesion but no CIN3+. Recalculation of sensitivity and speciﬁc-
ity when assessing FAM19A4 only resulted in an identical
sensitivity of 77.8% and a nonsigniﬁcantly higher speciﬁcity
of 70.6%.
Figure 1. Flowchart of the ﬁrst 601 women that were included in the EVAH study in Barcelona with cross-sectional results of the referral
smear, hrHPV testing and genotyping and methylation testing. Results are presented as percentages with a positive test result per
histological diagnosis category.
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Combinations of triage markers
Table 1b shows the sensitivity, speciﬁcity, PPV and NPV of
different combinations of hrHPV testing, hrHPV genotyping
and methylation testing for the detection of CIN3+ in biopsies
of women referred after abnormal cytology, and Table 2b
shows this for the outcome of CIN3 only. Among the different
combinations that were made, the combination of HPV16/18
and/or methylation positivity had the highest speciﬁcity
(49.4%, 95% CI 44.8–53.9), while sensitivity was comparable
to that of methylation testing combined with testing for all
hrHPV or HPV16/18/31/45.
As the combination of HPV16/18 and/or methylation posi-
tivity performed best among the combinations, with the highest
speciﬁcity and comparable sensitivity, PPV and NPV, this com-
bination was used in further analyses. In these analyses, the
combination of HPV16/18 and/or methylation was compared to
the single triage markers with the highest sensitivity (hrHPV)
and highest speciﬁcity and NPV:methylation (Table 1).
Performance of hrHPV testing and methylation for the
detection of CIN3+ in women <30 and ≥30 years of age with
ASC-US/LSIL and ASC-H/HSIL cytology.
Table 3 shows the sensitivity, speciﬁcity, PPV and NPV for
the detection of CIN3+ by hrHPV testing, hrHPV genotyping
and methylation in women <30 and ≥30 years of age with
ASC-US/LSIL and ASC-H/HSIL referral cytology.
Women <30 years of age
The group of women <30 years of age consisted of 171 women,
of whom 16 had an HSIL/CIN3 lesion and none had ICC.
Age ranged from 18 to 29 with a mean of 25.4 years. In this
group, HPV16/18 was found in 68.8% of the women with
CIN3+. Sensitivity of hrHPV testing (93.8%, 95% CI
71.7–98.9) was signiﬁcantly higher than that of methylation
testing (37.5%, 95% CI 18.5–61.4) (p = 0.004), whereas the
speciﬁcity of methylation analysis (85.8%, 95% CI 79.4–90.4)
was signiﬁcantly higher than that of hrHPV testing (26.5%,
95% CI 20.1–33.9) (p < 0.001). The performance of the com-
bination of HPV16/18 and/or methylation positivity provided
the optimal balance between sensitivity (75.0%, 95%CI
50.5–89.8) compared to methylation analysis (p = 0.031) and
speciﬁcity (55.5%, 95% CI 47.6–63.1) compared to hrHPV
testing (p < 0.001).
Only 3/16 CIN3+ lesions were found among women with
ASC-US/LSIL referral cytology and, therefore, 95% conﬁdence
intervals in this group are wide making the performance of all
markers as a triage test for CIN3+ detection comparable.
However, the speciﬁcity of HPV16/18 and/or methylation
(64.75, 95% CI 54.8–73.4) was signiﬁcantly higher than that of
methylation analysis (32.3%, 95% CI 23.9–42.1) (p < 0.001).
Most CIN3+ lesions were found in women with ASC-H/HSIL
referral cytology (13/16 CIN3+ lesions). In this group, the
sensitivity of HPV16/18 and/or methylation (92.3%, 95% CI
66.7–98.6) was higher than that of methylation analysis
(38.5%, 95% CI 17.7–64.5) (p = 0.061), but the speciﬁcity of
methylation analysis (87.6%, 95%CI 66.2–87.3) was signiﬁ-
cantly higher than that of HPV16/18 and/or methylation
(16.1%, 95% CI 8.8–27.8) (p < 0.001) and hrHPV testing
(39.3%, 95% CI 27.6–52.4) (p < 0.001).
Figure 2. FAM19A4 and miR124-2 positivity (%) in different grades of
CIN in all women.
Table 1. (a) Sensitivity, specificity, PPV and NPV of hrHPV testing, hrHPV genotyping and methylation testing and (b) different combinations
(1b) for the detection of CIN3+ (CIN3 and invasive carcinoma) in biopsies of women referred after abnormal cytology
All women (N = 538)
Sensitivity (%) 95% CI
Speciﬁcity
(%) 95% CI PPV (%) 95% CI NPV (%) 95% CI
(a) Single triage tests
hrHPV testing 90.3 81.3–95.2 31.8 27.7–36.1 17.0 13.5–21.1 95.5 91.0–97.8
HPV16/18/31/45 75.0 63.9–83.6 55.6 51.0–60.0 20.7 16.2–26.0 93.5 90.0–95.9
HPV16/18 62.5 51.0–72.8 69.3 65.0–73.3 23.9 18.4–30.5 92.3 89.0–94.6
Methylation (FAM19A4/miR124-2) 77.8 66.9–85.8 69.3 65.0–73.3 36.4 29.8–43.6 98.3 96.1–99.3
(b) Combinations of triage tests
hrHPV and/or methylation 98.6 92.5–99.8 24.3 20.6–28.3 16.8 13.5–20.6 99.1 95.2–99.8
HPV16/18/31/45 and/or methylation 95.8 88.5–98.6 39.7 35.4–44.2 19.7 15.9–24.2 98.4 95.4–99.5
HPV16/18 and/or methylation 93.1 84.8–97.0 49.4 44.8–53.9 22.1 17.8–27.1 97.9 95.1–99.1
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Women ≥30 years of age
The group of women ≥30 years (mean 41.3 years, range
30–75) consisted of 367 women, 56 of whom had CIN3+
(50 CIN3, 6 ICC). HPV16/18 was detected in the smear of
60.7% of the women with CIN3+. Sensitivity of hrHPV testing
and methylation analysis in this population were the same
(89.3%, 95% CI 78.5–95.0), but the speciﬁcity of methylation
analysis (61.1%, 95% CI 55.6–66.3) was signiﬁcantly higher
than that of hrHPV testing (34.4%, 95% CI 29.3–39.9)
(p < 0.001). The combination of HPV16/18 and/or methyla-
tion positivity resulted in an increase in sensitivity to 98.2%
(p = 0.063) and speciﬁcity of 46.3% which was improved com-
pared to hrHPV testing (p < 0.001).
In this group, 3/56 CIN3+ lesions were found in women
with ASC-US/LSIL cytology leading to overlapping 95% conﬁ-
dence intervals of the performance of all three markers. The
only woman with ASC-US cytology and a CIN3 lesion was
among these women, smear which was hrHPV negative and
methylation positive. 53/56 CIN3+ lesions were found in
women with ASC-H/HSIL. All three tests performed equally
well regarding sensitivity, PPV and NPV, but the speciﬁcity of
methylation analysis (48.9%, 40.8–57.1) was signiﬁcantly
higher than that of HPV16/18 and/or methylation (31.9%,
95% CI 24.8–40.0) (p < 0.001) and hrHPV testing (26.2%,
95% CI 19.7–34.1) (p < 0.001).
Discussion
This study explored different triage tests and combinations for
CIN3+ detection in a population of women referred to colpos-
copy because of abnormal cytology, including women younger
and older than 30 years. Many studies have investigated
repeated cytology, reﬂex hrHPV testing and genotyping for
HPV16/18 as triage tests in patients referred to colposcopy
clinic.19,20 This study examined, in addition, the value of a test
for methylation of two speciﬁc tumor suppressor genes
(FAM19A4 and miR124-2). It compared the results with those
of hrHPV triage, and evaluated the potential combinations of
hrHPV testing, including genotyping, with methylation analy-
sis. A combination of HPV16/18 genotyping and/or methyla-
tion positivity performed well, with a high sensitivity (93.1%)
and moderate speciﬁcity (49.4%) for ≥CIN3. This combina-
tion performed particularly well in women ≥30 years of age
(sensitivity 98.2% and speciﬁcity 46.3%). In women with
≤LSIL, the study offered an adequate balance between sensi-
tivity (83.3%) and speciﬁcity (60.6%). The results indicate that
the combination of the two biomarkers (HPV16/18 genotyp-
ing and/or methylation positivity) could separate women into
risk groups more accurately than either HPV genotyping or
methylation analysis alone.
The diagnostic performance of the combined testing is
based on the importance of HPV16/18 in ICC and in HSIL/
CIN3,21,22 and the presence of methylation in advanced pre-
cancers and ICC. Methylation testing with markers FAM19A4
and miR124-2 on physician-taken smears had a sensitivity for
ASC-H/HSIL/CIN3 detection of 77.8% and a speciﬁcity of
69.3% for the overall population. Interestingly, the sensitivity
and speciﬁcity of the methylation analysis in women 30 years
of age and over were particularly high (89.3% and 61.1%,
respectively). This is in line with ﬁndings by Luttmer et al.,
who found an association between age and the performance
of FAM19A4 as a triage test in hrHPV-screened women, mak-
ing it an attractive marker for women ≥30 years.23 Positivity
for miR124-2 and/or FAM19A4 detected all ICC, and 75.8%
of HSIL/CIN3 lesions in the overall population, suggesting
that the combination of these biomarkers identiﬁes the most
severe precancerous lesions.
The accurate identiﬁcation of women who have histological
HSIL/CIN3, within the subset of women with abnormal
smears prior to colposcopy and biopsy, is potentially very
important in avoiding overinvestigation and overtreatment.
Even among women with cytological HSIL, many will not
have HSIL/CIN3 or ICC. In this study, only 25% of these
women had histological ASC-H/HSIL/CIN3. hrHPV testing
has shown high sensitivity for HSIL/CIN3 detection24–27 and
Table 2. (a) Sensitivity, specificity, PPV and NPV of hrHPV testing, hrHPV genotyping and methylation testing and (b) different combinations for
the detection of CIN3 in biopsies of women referred after abnormal cytology
All women (N = 538; total number of women is 538)
Sensitivity
(%) 95% CI
Speciﬁcity
(%) 95% CI PPV (%) 95% CI NPV (%) 95% CI
(a) Single triage tests
hrHPV testing 90.9 81.6–95.8 31.8 27.7–36.1 15.9 12.5–19.9 96.1 91.8–98.2
HPV16/18/31/45 74.2 62.6–83.3 55.6 51.0–60.0 19.1 14.8–24.4 93.8 90.4–96.1
HPV16/18 62.1 50.1–72.9 69.3 65.0–73.3 22.3 16.9–28.8 92.8 89.6–95.1
Methylation (FAM19A4/miR124-2) 75.8 64.2–84.5 69.3 65.0–73.3 25.9 20.2–32.5 95.3 92.5–97.1
(b) Combinations of triage tests
hrHPV and/or methylation 98.5 91.9–99.7 24.3 20.6–28.3 15.6 12.4–19.3 99.1 95.2–99.8
HPV16/18/31/45 and/or methylation 95.5 87.5–98.4 39.7 35.4–44.2 18.3 14.6–22.7 98.4 95.4–99.5
HPV16/18 and/or methylation 92.4 83.5–96.7 49.4 44.8–53.9 20.5 16.3–25.5 97.9 95.1–99.1
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in many Western countries, hrHPV testing already has a place
in screening, either as a stand-alone screening test or in com-
bination with cytology, or in triage. However, using the clini-
cally validated GP5+/6+-PCR-EIA for triage of women with
≥ASC-US on screening, hrHPV positivity showed high sensi-
tivity (90.3%) but the lowest speciﬁcity (31.8%). This results
in potential overtreatment of a large number of women who
are not at high short-term risk of cancer, and who may have
regressing lesions.
The results obtained in this study are in keeping with pre-
vious evidence showing that older age and longer duration of
hrHPV infection are associated with methylation positive
HSIL/CIN3+.14,28,29 These ﬁndings suggest that further inves-
tigation of whether the current practice of treating all histo-
logically conﬁrmed ASC-H/HSIL/CIN2 by LLETZ could be
modiﬁed to provide more selective individual management of
women with screen-detected cervical abnormalities. Current
thresholds for referral to colposcopy and treatment are based
on the risk of HSIL/CIN2+.30 This leads to unnecessary refer-
ral and overtreatment of women with lesions that have a low
short-term risk of progression and a deﬁnite probability of
regression.31 Our methylation results demonstrate heterogene-
ity in HSIL/CIN2 and HSIL/CIN3. It is important to investi-
gate in prospective studies whether combined methylation
and HPV16/18 testing could be used in practice to distinguish
methylation positive women, who need urgent further investi-
gation and treatment, from women who are methylation-
negative but positive for HPV16/18 and could be followed at
appropriate intervals for regression to avoid unnecessary
treatment.
This study has a number of limitations. The study was rel-
atively small and only one woman with ASC-US and ﬁve
women with LSIL cytology had HSIL/CIN3+. Also, patients
were not selected for treatment on the basis of the results of
the methylation biomarkers. When the methylation bio-
markers were studied individually, FAM19A4 was positive in
all methylation-positive HSIL/CIN3+ lesions, but only
miR124-2 was positive in ﬁve women with negative and LSIL/
CIN1 biopsies. In the studied population, the additive value of
miR124-2 in the detection of CIN3+ and squamous cell carci-
noma seems limited. Its beneﬁt seems more evident in avoid-
ing unnecessary biopsies (i.e., increase negative predictive
value) when FAM19A4 is positive and miR124-2 is negative.
Further investigation of the use of these methylation markers
individually requires large-scale clinical trials conducted under
careful supervision.
This was a cytology-screened referral population including
women who were screened opportunistically without prior
screening. Therefore, the prior probability of cytological and
histological abnormalities might have been higher32 and
results from this study cannot be directly extrapolated to
screening by hrHPV testing alone or co-testing with cytology.
The consistency, however, with other studies of primary HPV
screening suggests that the principles identiﬁed here could beTa
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applied to different screening strategies.33–35 Colposcopy was
used to identify possible lesions. To address the limitations to
the accuracy of colposcopy and taking of biopsies,36,37 multi-
ple biopsies were taken, endocervical curettage, and a random
biopsy in every woman who had <4 lesion-directed biopsies to
improve detection of lesions.
This study shows the potential for early accurate identiﬁca-
tion of HSIL/CIN3+ by testing for hrHPV and methylation
of human tumor suppressor genes in routine liquid-based
cervical cytological samples. It suggests that HSIL/CIN3 is a
heterogeneous group, consisting of methylation positive
lesions and methylation negative lesions. We hypothesize that
methylation positive HSIL/CIN3 lesions are advanced trans-
forming lesions and are mostly detected in women ≥30 years
of age with a persisting hrHPV infection.28 The methylation
negative HSIL/CIN3 lesions may be found in younger women
caused by HPV infections of a shorter duration or infections
that follow a different pathway.29,38 Further, larger, follow-up
studies in different screened populations are needed to investi-
gate whether a combination of HPV16/18 typing and methyl-
ation testing is feasible for stratifying clinical management.
To evaluate further the heterogeneity of high-grade precan-
cer lesions, more markers should be evaluated. Such potential
markers include methylation of more human genes, methyla-
tion of HPV DNA, study of miRNAs, study of somatic and
germline SNPs and use of immunohistochemical marker pat-
terns such as p16INK4a and HPV E4 to distinguish transform-
ing and productive elements in CIN lesions. The development
and clinical evaluation of these markers in prospective studies
opens up the possibility of early and reliable identiﬁcation of
women who need rapid treatment of HSIL/CIN3 at high risk
of progression to ICC or have ICC and avoid unnecessary
treatment of potentially regressing HSIL/CIN2.
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